Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

Pieter Sonneveld,Evangelos Terpos,Meletios A. Dimopoulos,Jon Ukropec,Elena Smith,Nienke Houkes,Jordan Schecter,Efstathios Kastritis

Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

2018

Pieter Sonneveld
Evangelos Terpos
Meletios A. Dimopoulos
Jon Ukropec
Elena Smith
Nienke Houkes
Jordan Schecter
Efstathios Kastritis

TPS8059Background: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved in the United States and Europe for use as a monotherapy and in combination with bortezomib/dexamethasone or le...

Keywords:

Refractory Multiple Myeloma
Dexamethasone
Daratumumab
Pomalidomide
Phases of clinical research
Dara
Oncology
Pathology
Internal medicine
Medicine
in patient
Bortezomib
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations